Bailard’s Atara Biotherapeutics ATRA Stock Holding History

Bailard’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-602	Closed	-$237K	–	725
2021 Q4	$237K	Buy	+602	New	+$253K	0.01%	628

Other funds holding ATRA

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bailard's ATRA Position: Q1 2022 in Review

Bailard sold out of Atara Biotherapeutics (ATRA) in Q1 2022, closing a stake of 602 shares — an estimated $237K sold.

Bailard first reported a position in ATRA in Q4 2021 and held it in 1 quarter. The position peaked at $237K in Q4 2021. 144 funds tracked by Wall St. Rank hold ATRA as of Q1 2022.

Bailard reported no remaining Atara Biotherapeutics position as of Q1 2022 after selling out during the quarter.
Bailard sold 602 Atara Biotherapeutics shares in Q1 2022, an estimated $237K.
Bailard first reported a position in Atara Biotherapeutics in Q4 2021 and held it in 1 quarter.
Bailard's Atara Biotherapeutics position peaked at $237K in Q4 2021.
144 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2022.

Based on Bailard's 13F filing for Q1 2022, filed 25 Apr 2022.